318 related articles for article (PubMed ID: 33830087)
1. Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata.
Dai Z; Chen J; Chang Y; Christiano AM
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830087
[TBL] [Abstract][Full Text] [Related]
2. Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata.
Dai Z; Sezin T; Chang Y; Lee EY; Wang EHC; Christiano AM
Front Immunol; 2022; 13():955038. PubMed ID: 36203601
[TBL] [Abstract][Full Text] [Related]
3. Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease.
Lescoat A; Lelong M; Jeljeli M; Piquet-Pellorce C; Morzadec C; Ballerie A; Jouneau S; Jego P; Vernhet L; Batteux F; Fardel O; Lecureur V
Biochem Pharmacol; 2020 Aug; 178():114103. PubMed ID: 32562787
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of JAK-STAT Signaling Suppresses Pathogenic Immune Responses in Medium and Large Vessel Vasculitis.
Zhang H; Watanabe R; Berry GJ; Tian L; Goronzy JJ; Weyand CM
Circulation; 2018 May; 137(18):1934-1948. PubMed ID: 29254929
[TBL] [Abstract][Full Text] [Related]
5. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
6. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
7. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
[TBL] [Abstract][Full Text] [Related]
8. High-throughput T cell receptor sequencing identifies clonally expanded CD8+ T cell populations in alopecia areata.
de Jong A; Jabbari A; Dai Z; Xing L; Lee D; Li MM; Duvic M; Hordinsky M; Norris DA; Price V; Mackay-Wiggan J; Clynes R; Christiano AM
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282836
[TBL] [Abstract][Full Text] [Related]
9. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells.
Kim JE; Lee YJ; Park HR; Lee DG; Jeong KH; Kang H
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32698510
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
11. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
12. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.
Xing L; Dai Z; Jabbari A; Cerise JE; Higgins CA; Gong W; de Jong A; Harel S; DeStefano GM; Rothman L; Singh P; Petukhova L; Mackay-Wiggan J; Christiano AM; Clynes R
Nat Med; 2014 Sep; 20(9):1043-9. PubMed ID: 25129481
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
14. A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function.
De Vries LCS; Duarte JM; De Krijger M; Welting O; Van Hamersveld PHP; Van Leeuwen-Hilbers FWM; Moerland PD; Jongejan A; D'Haens GR; De Jonge WJ; Wildenberg ME
Inflamm Bowel Dis; 2019 Mar; 25(4):647-660. PubMed ID: 30668755
[TBL] [Abstract][Full Text] [Related]
15. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
16. An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
Lensing M; Jabbari A
Front Immunol; 2022; 13():955035. PubMed ID: 36110853
[TBL] [Abstract][Full Text] [Related]
17. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
18. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
20. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]